Ceravise Tablet 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
MFDS item code 201906588 · Approved 2019.09.20
This product's status changed to Expired on 2024.09.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
Amlodipine or Olmesartan Medoxomil is used when blood pressure control is not adequate with monotherapy in patients with essential hypertension. These medications effectively lower blood pressure, reducing the risk of cardiovascular complications. Continuous use is important as it can greatly assist in maintaining a healthy blood pressure for the patient. This treatment improves hypertension and enhances overall health.
This medicine is administered as 1 tablet once daily with water, regardless of food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with decreased effective intravascular volume: For patients who may have decreased effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment (see section 2, Contraindications). ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
The safety and efficacy in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this medication or have severe liver dysfunction should not take it. Women who are pregnant or breastfeeding should also avoid this medication, and caution is needed for patients with certain cardiac valve diseases or biliary obstruction. Patients with fluid or salt depletion may experience hypotension at the start of treatment; therefore, their condition must be monitored closely, and appropriate measures should be taken if hypotension occurs. Patients with heart or blood vessel issues, particularly severe heart failure or obstructive coronary artery disease, should take caution when using this medication. Patients with poor renal function should have their kidney function monitored regularly, as this medication may affect the kidneys. Patients with impaired liver function should also take caution with this medication; dosage adjustments may be required. This medication can cause various side effects, commonly dizziness, headache, hypotension, edema, indigestion, etc. Rarely, serious allergic reactions, hepatitis, and kidney issues may occur, so if any unusual symptoms arise, the patient should consult a doctor immediately. Drug interactions may occur during the course of this medication, so patients should inform their healthcare provider of any other medications they are taking. Especially, it is advisable to avoid taking this medication with grapefruit juice, as it can excessively increase its effect. This medication should not be taken during pregnancy, and if planning to conceive, it is recommended to switch to a safer treatment option. Breastfeeding women should also consider stopping breastfeeding or discontinuing this medication, as it may affect the baby. This medication is not recommended for children under 18 years of age as its safety and efficacy have not been established. Elderly patients may be more sensitive to this medication and should start with a lower dose and be managed carefully. In case of overdose, severe hypotension and vasodilation may occur, requiring immediate medical treatment. This medication should be stored in a tightly sealed container, protected from direct sunlight and moisture, and out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to keep it at room temperature between 1 to 30 degrees Celsius.
Light yellow round film-coated tablet
30 tablets/PTP [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.